spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Streptococcus pyogenes 

 HSMN NewsFeed - 2 Jul 2020
Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Dec 2017
Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi(TM) (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 5 Oct 2017
Cepheid Expands Respiratory Disease Portfolio with Xpert Xpress Strep A
Diagnostics FDA
 HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch
 HSMN NewsFeed - 15 Sep 2016
Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jan 2016
Vernalis Announces Corvus Pharmaceuticals, Inc. as Its Worldwide Licensee for Their Adenosine Antagonist Program
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Jan 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2014
Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test for Group A Strep
Diagnostics FDA
 HSMN NewsFeed - 18 Jul 2014
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 30 Dec 2013
Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Sep 2011
Nexera Medical, Inc. Announces That It Plans to Submit New Data to the U.S. Food and Drug Administration (FDA) to Amend Its Current 510k Medical Device Clearance to Include Certain Strains of Viruses
Devices
 HSMN NewsFeed - 30 Oct 2010
Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Oct 2008
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 May 2008
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Feb 2008
Cubist Pharmaceuticals Names Steven C. Gilman, Ph.D., as Senior Vice President, Discovery and Non-Clinical Development and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2008
FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Oct 2007
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 6 Sep 2007
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jul 2007
Positive Opinion for Expanded Label of CUBICIN Received from European Regulatory Authority; Decision Expected This September
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jun 2007
Advancis Pharmaceutical Reports on Meeting with FDA Reviewing Keflex PULSYS Phase III Trial Design
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 22 May 2007
Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Apr 2007
GSK Announces FDA Approval of Altabax(TM) (Retapamulin Ointment), 1%
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2007
Advancis Pharmaceutical Resubmits New Drug Application for Once-Daily Amoxicillin PULSYS
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2007
Advancis Pharmaceutical Reaches Agreement with FDA for Resubmission of Amoxicillin PULSYS NDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2006
FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2006
Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in China to AstraZeneca
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Sep 2006
Efficacy of Once-Daily AVELOX(R) in Treating Complicated Intra-Abdominal Infections Highlighted in Two Clinical Data Presentations at ICAAC
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
Streptococcus pyogenes
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!